AT-rich DNA minor groove in Clostridioides difficile

The AT-rich DNA minor groove in Clostridioides difficile is a specialized pharmacological target for narrow-spectrum antibiotics, most notably ridinilazole (SMT19969). The C. difficile genome is characterized by a high adenine-thymine (AT) content of approximately 71%, which creates specific structural motifs in the DNA minor groove that can be selectively targeted by small-molecule binders (He et al., 2010; Vickers et al., 2015). Binding of therapeutic agents to these sites physically interferes with the binding of essential proteins, including DNA polymerases and transcription factors, effectively halting DNA replication and the expression of key virulence factors such as toxins A and B (Basseres et al., 2016). This mechanism is highly effective in treating Clostridioides difficile infections (CDI) while minimizing damage to the host's protective gut microbiome, as the selectivity of these drugs often favors the specific AT-rich architecture of the pathogen over commensal species (Cho et al., 2019). By inhibiting both pathogen proliferation and toxin production, targeting the minor groove addresses both the acute symptoms and the high recurrence rates associated with CDI.

Other names

Bacterial DNA minor grooveAT-rich DNA sequencesMinor groove of Clostridioides difficile DNAC. difficile DNA minor groove

Minor groove binding leading to inhibition of DNA replication and transcription of virulence factors